Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CMOP in Newly Diagnosed DLBCL
NCT06594640Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06594640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594640.